Figure S2 from Clinical Validity of HPV Circulating Tumor DNA in Advanced Anal Carcinoma: An Ancillary Study to the Epitopes-HPV02 Trial

Résumé fourni par la source

Figure S2 shows the ROC curve analysis of progression prediction according to the HPV ctDNA level at baseline. (AUC was 0.646 (95% CI 0.49 to 0.802) and 2940 copies/ml was determined as the ctDNA cut-off level for comparison. Sensitivity and specificity of the cut-off were 67% and 70% respectively).